Daniel Bruetman, MD
Medical Oncology · Chicago, ILNPI 1972583417
Payments from drug & device makers
Across 101 payments — averaging $3180.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$250K
- Merck$64K
- Macrogenics, Inc.$3K
- Gilead$2K
- Janssen Research & Development, LLC$540
- E.r. Squibb & Sons, L.L.C.$133
- plus $2K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $249,500 |
| Merck | 21 | $64,307 |
| Macrogenics, Inc. | 1 | $3,031 |
| Gilead | 10 | $2,248 |
| Janssen Research & Development, LLC | 1 | $540 |
| E.r. Squibb & Sons, L.L.C. | 6 | $133 |
| Genentech USA, Inc. | 2 | $132 |
| Johnson & Johnson | 6 | $127 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Pfizer | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| AstraZeneca | 4 | $98 |
| AbbVie | 3 | $77 |
| Incyte Corporation | 4 | $74 |
| Ipsen Biopharmaceuticals, Inc | 1 | $70 |
| Seagen Inc. | 4 | $67 |
| Amgen | 3 | $66 |
| Global Blood Therapeutics, Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $40 |
| Springworks Therapeutics, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $24 |
| Verastem, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Bristol Myers Squibb | 1 | $21 |
| Cardinal Health 414 LLC | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $11 |
How this compares
$321,266 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.